Structure-Activity Study of Anti-inflammatory Trioxoper-
hydropyrimidine Derivatives¹⁾EIJI MIZUTA, NOBUO SUZUKI, YUTAKA MIYAKE, MASAO NISHIKAWA,^{2a)}
and TOSHIO FUJITA^{2b)}Central Research Division, Takeda Chemical Industries, Ltd.^{2a)} and Department
of Agricultural Chemistry, Kyoto University^{2b)}

(Received April 4, 1974)

Regression analyses using the Free-Wilson technique were applied to the anti-inflammatory effect and the acute toxicity of 57 1,3,5-trisubstituted 2,4,6-trioxoperhydropyrimidine derivatives. Models for the orientation of substituents on the "receptor site" are presented. A significant correlation was obtained by assuming that one of the N-substituents with a high hydrophobicity always locates at a particular binding site. Further analysis of the contributions of substituents at the 5-position using the free energy related hydrophobic parameter, π revealed that acute toxicity increases with an increase in the hydrophobicity of the 5-substituents. 1-Cyclohexyl-5-butyl or -allyl derivatives seemed to be the most suitable anti-inflammatory agents in terms of their high activity and low toxicity.

A number of di- and tri-substituted 2,4,6-trioxoperhydropyrimidines, shown in Fig. 1, were synthesized by Senda, *et al.*^{3a)} and their anti-inflammatory effect and acute toxicity, were measured by Fujimura, *et al.*³⁾ Among these, 5-*n*-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (Bucolome^R) has been widely used as an effective anti-inflammatory drug with low toxicity and few side effects. We here report the structure-activity relationship of these derivatives, including Bucolome.

Fig. 1. Assignment of Substituents

Compounds with different substituents at the 1- and 3-positions have an asymmetric carbon atom at the 5-position. Racemic mixtures of these compounds have been used to measure the acute toxicity and anti-inflammatory effects. The pK_a value of 5-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine is reported to be 4.4.⁴⁾ We assume that other trioxoper-

1) The 92th Annual Meeting of Pharmaceutical Society of Japan, Osaka, April 1972.

2) Location: a) Juso-Nishino-cho, Higashiyodogawa-ku, Osaka; b) Sakyo-ku, Kyoto.

3) a) S. Senda, H. Izumi, and H. Fujimura, *Arzneimittel-Forsch.*, **17**, 1519 (1967); b) H. Fujimura, S. Tsurumi, M. Hayashi, M. Ushijima, T. Ezaki, Y. Suzuki, and M. Ito, *Nihon Yakurigaku Zasshi*, **63**, 43 (1967).4) H. Mima, Y. Asahi, K. Terada, T. Matsuzaki, E. Mizuta, and H. Izumi, *Takeda Kenkyusho Nempo*, **24**, 1 (1965).

hydropyrimidine derivatives show nearly the same pK_a value. Therefore, these compounds will probably almost completely dissociate into ions at the 5-position in living systems under physiological conditions so that the (+)- and (−)-derivatives are no longer distinguishable from each other. This means that when administered to living systems, the racemic compounds would have the same biological activities as the individual administration of the (+)- or (−)-derivatives.

TABLE I. Models for the Location of Substituents

A			B			C		
R_1	R_3	Weight	R_1	R_3	Weight	R_1	R_3	Weight
Cyc-C ₆ H ₁₁	H	1	Cyc-C ₆ H ₁₁	H	1	{Cyc-C ₆ H ₁₁	H	0.5
C ₆ H ₅	H	1	C ₆ H ₅	H	1	{H	Cyc-C ₆ H ₁₁	0.5
Cyc-C ₆ H ₁₁	Cyc-C ₆ H ₁₁	1	Cyc-C ₆ H ₁₁	Cyc-C ₆ H ₁₁	1	{C ₆ H ₅	H	0.5
Cyc-C ₆ H ₁₁	C ₆ H ₅	1	C ₆ H ₅	Cyc-C ₆ H ₁₁	1	{H	C ₆ H ₅	0.5
C ₆ H ₅	C ₆ H ₅	1	C ₆ H ₅	C ₆ H ₅	1	Cyc-C ₆ H ₁₁	Cyc-C ₆ H ₁₁	1
						{Cyc-C ₆ H ₁₁	C ₆ H ₅	0.5
						{C ₆ H ₅	Cyc-C ₆ H ₁₁	0.5
						C ₆ H ₅	C ₆ H ₅	1

In the present study we assumed that the substituents R_1 , R_3 and R_5 of the trioxoperhydropyrimidine derivatives play specific roles at each position. This is easily understandable if we speculate, for example, that the substituents interact with different binding areas ρ_1 , ρ_2 and ρ_3 , respectively, on the receptor site. Based on this assumption, three models A, B, and C are presented for the orientation of substituents as shown in Table I. In model A substituent R_1 , which has an affinity for the ρ_1 area, is always more lipophilic than substituent R_3 . In model B, the ρ_1 area prefers an aromatic group to a lipophilic one. In the symmetric C model, the ρ_1 and ρ_2 areas have no such selectivities as in models A and B. Substituents R_1 and R_3 interact with the binding areas ρ_1 and ρ_2 with the same probability. In Table I, the figures of the column, weight, show the probability with which each substituent pair interacts with the binding sites, ρ_1 and ρ_2 . We have attempted to analyze the structure-activity relationship by using these three models to estimate the contribution of substituents to biological activity. Note that ρ_1 , ρ_2 and ρ_3 are not necessarily the true binding areas on the receptor site. They merely represent the location of substituents classified according to their roles in eliciting biological activity.

Calculations

Regression analyses using the Free-Wilson method⁵⁾ assume that the biological activity of a compound is the mathematical sum of the contributions of the substituents and parent skeleton, as represented by Eq. 1. In this equation, Y represents the magnitude of the biological activity. G_i is the log activity

5) S.H. Free, Jr. and J.W. Wilson, *J. Med. Chem.*, **7**, 395 (1964); T. Fujita and T. Ban, *ibid.*, **14**, 148 (1971).

$$\log Y = \sum G_i X_i + c$$

Eq. 1

contribution or the log activity enhancement factor of the i -th substituent. X_i takes the value of 1 or 0, depending on the presence or absence of the i -th substituent at each position. The numbering of the substituents is shown in Fig. 1. Unfortunately, no biological activities for the unsubstituted compound have been observed. Therefore, analyses based on Eq. 1 were performed by employing the overall average of the log activity values in this set of compounds for the term c .

Results

1) Acute Toxicity of Trioxoperhydropyrimidine Derivatives

The acute toxicity of 49 trioxoperhydropyrimidine derivatives have been reported by Senda, *et al.*^{3a)} The reciprocals of the LD₅₀ values (mm/100 g) used in the present analysis were calculated from their data. Eq. 2 was obtained by applying Eq. 1 to the symmetric C model. Eqs. 3 and 4 were derived from applications

With model C:

$$\log Y = \sum G_i X_i + c \quad \begin{matrix} n & r & s & F & \begin{matrix} (\phi_1) \\ (\phi_2) \\ (15) \\ (33) \end{matrix} \end{matrix} \quad \text{Eq. 2}$$

With model A:

$$\log Y = \sum G_i X_i + c \quad \begin{matrix} n & r & s & F & \begin{matrix} (16) \\ (32) \end{matrix} \end{matrix} \quad \text{Eq. 3}$$

With model B:

$$\log Y = \sum G_i X_i + c \quad \begin{matrix} n & r & s & F & \begin{matrix} (16) \\ (32) \end{matrix} \end{matrix} \quad \text{Eq. 4}$$

of Eq. 1 for models A and B, respectively. In all the equations n is the number of compounds included in the analysis, r is the correlation coefficient and s is the standard deviation. Correlations between the observed and calculated activities in Eqs. 2 and 4 were poor and their correlation coefficients were not significantly different from zero. A fairly good correlation was observed in Eq. 3 obtained for model A. In equation 3, the F ratio between the variances of the calculated and observed activities was significant at the 97.5% level. Thus, it is conceivable that one of the 1- and 3-substituents, which is more hydrophobic than the other, plays a similar role in biological activity. One of the two binding areas, ρ_1 or ρ_2 , may have a stronger affinity for lipophilic substituents than the other. When substituent R_5 is a phenyl or cyclohexyl group and is identical or closely resembles substituent R_1 or R_3 (Compounds No. 13, 14, 20, 21, 31, 32, 40, 48, and 49 in Table II), large differences are found between the observed and calculated values as shown in Table II. Some of these are predicted to be more toxic and others less toxic than was observed. These differences may be attributed to the steric limitation of the ρ_3 area. Another possibility might be that a quasi symmetry is involved in these compounds. Substituent R_5 may play a role which would otherwise be that of hydrophobic R_2 or the R_3 substituent.

The analysis of the structure-activity relationship based on model A, excluding these nine derivatives, led to Eq. 5.

$$\log Y = \sum G_i X_i + c \quad \begin{matrix} n & r & s & F & \begin{matrix} (14) \\ (25) \end{matrix} \end{matrix} \quad \text{Eq. 5}$$

The correlation was much improved over that of Eq. 3. The F ratio between the variances of the calculated and observed activities was significant at the 99.5% level. The log activity

contribution values G_i s using Eqs. 3 and 5 for the acute toxicity are listed in Table III. The calculated total activity of each compound is shown in Table II.

TABLE II. Observed and Calculated $-\log LD_{50}$ Values of Trioxoperhydropyrimidine Derivatives

	R_1	R_3	R_5	Obsd.	Calcd. from	
					Eq. 3	Eq. 5
1	Cyc-C ₆ H ₁₁	H	CH ₃	0.647	0.752	0.729
2			C ₂ H ₅	0.995	0.785	0.762
3			C ₃ H ₇	0.875	0.843	0.820
4			iso-C ₃ H ₇	0.789	0.942	0.884
5			CH ₂ CH=CH ₂	0.809	0.878	0.855
6			C ₄ H ₉	0.685	0.883	0.860
7			iso-C ₄ H ₉	0.887	0.863	0.881
8			sec-C ₄ H ₉	0.908	0.731	0.749
9			C ₅ H ₁₁	0.936	0.924	0.890
10			sec-C ₅ H ₁₁	0.985	0.775	0.793
11			C ₆ H ₁₃	1.067	1.067	1.067
12			C ₈ H ₁₇	1.141	1.141	1.141
13			Cyc-C ₆ H ₁₁	1.003	0.945	
14			C ₆ H ₅	1.025	0.829	
15	C ₆ H ₅	H	CH ₃	0.483	0.492	0.445
16			C ₂ H ₅	0.255	0.524	0.478
17			C ₃ H ₇	0.467	0.583	0.536
18			CH ₂ CH=CH ₂	0.442	0.618	0.571
19			C ₄ H ₉	0.666	0.623	0.576
20			Cyc-C ₆ H ₁₁	1.145	0.685	
21			C ₆ H ₅	0.243	0.569	
22	Cyc-C ₆ H ₁₁	Cyc-C ₆ H ₁₁	CH ₃	0.646	0.525	0.466
23			C ₂ H ₅	0.501	0.557	0.498
24			C ₃ H ₇	0.427	0.616	0.557
25			CH ₂ CH=CH ₂	0.857	0.650	0.591
26			C ₄ H ₉	0.691	0.656	0.597
27			iso-C ₄ H ₉	0.612	0.636	0.618
28			sec-C ₄ H ₉	0.326	0.503	0.485
29			C ₅ H ₁₁	0.569	0.697	0.626
30			sec-C ₅ H ₁₁	0.338	0.548	0.530
31			Cyc-C ₆ H ₁₁	0.740	0.718	
32			C ₆ H ₅	0.998	0.602	
33	Cyc-C ₆ H ₁₁	C ₆ H ₅	CH ₃	1.155	1.023	1.099
34			C ₂ H ₅	1.135	1.055	1.132
35			C ₃ H ₇	1.198	1.114	1.190
36			iso-C ₃ H ₇	1.061	1.213	1.254
37			CH ₂ CH=CH ₂	1.296	1.149	1.225
38			C ₄ H ₉	1.140	1.154	1.230
39			C ₅ H ₁₁	1.112	1.195	1.260
40			Cyc-C ₆ H ₁₁	0.628	1.216	
41	C ₆ H ₅	C ₆ H ₅	CH ₃	0.622	0.763	0.815
42			C ₂ H ₅	0.831	0.795	0.848
43			C ₃ H ₇	1.044	0.854	0.906
44			iso-C ₃ H ₇	1.257	0.953	0.970
45			CH ₂ CH=CH ₂	0.778	0.889	0.941
46			C ₄ H ₉	1.028	0.894	0.946
47			C ₅ H ₁₁	1.134	0.935	0.976
48			Cyc-C ₆ H ₁₁	1.003	0.956	
49			C ₆ H ₅	0.574	0.840	

TABLE III. Calculated Group Contributions, G Values, of Trioxoperhydropyrimidine Derivatives

Position	i	Substituent	Acute toxicity		Anti-inflammatory effect		
			Calculated from Eq. 3	Eq. 5	Ovalbumin	Dextran	Carra-geenin
R_1	1'	Cyc-C ₅ H ₉					0.433
	1	Cyc-C ₆ H ₁₁	0.085	0.085	0.086	0.038	0.351
	2	C ₆ H ₅	-0.175	-0.199	-0.178	-0.078	-0.361
R_3	3	H	-0.043	-0.070	0.020	-0.012	0.041
	4	Cyc-C ₆ H ₁₁	-0.270	-0.334	-0.072	0.006	-0.474
	5	C ₆ H ₅	0.228	0.300	0.022	0.011	0.104
R_5	6	CH ₃	-0.110	-0.106	0.055	0.060	0.005
	7	C ₂ H ₅	-0.077	-0.073	0.018	-0.050	-0.018
	8	C ₃ H ₇	-0.018	-0.015	-0.034	0.001	-0.051
	9	iso-C ₃ H ₇	0.080	0.049	-0.041	-0.043	-0.051
	10	CH ₂ CH=CH ₂	0.016	0.020	0.101	0.163	0.043
	11	C ₄ H ₉	0.022	0.025	0.032	0.090	0.015
	12	iso-C ₄ H ₉	0.002	0.046	0.011	0.102	
	13	sec-C ₄ H ₉	-0.131	-0.086	-0.081	-0.328	
	14	C ₅ H ₁₁	0.063	0.055	0.007	-0.032	-0.083
	15	sec-C ₅ H ₁₁	-0.086	-0.041	-0.118	0.010	-0.248
	16	C ₆ H ₁₃	0.206	0.232	-0.127	-0.658	
	17	C ₈ H ₁₇	0.279	0.306	-0.127	0.019	
	18	Cyc-C ₆ H ₁₁	0.083		0.106	0.053	0.089
	19	C ₆ H ₅	-0.032		-0.166	-0.062	-0.018
	20	c	0.819	0.820	1.601	1.533	1.275

We analyzed the G values obtained for substituents at the 5-position using a free energy related hydrophobic substituent parameter, π .^{6,7)} Using the G values calculated from Eq. 5; Eqs. 6 and 7 were obtained by the method of least squares. In Eq. 6 the G values of the cyclohexyl and phenyl groups were excluded, and in Eq. 7 the exclusion was extended to the *sec*-butyl and *sec*-pentyl groups. The fact that the *sec*-butyl and *sec*-pentyl

$$G = 0.110\pi - 0.1205 \quad \begin{matrix} n & r & s \\ 12 & 0.847 & 0.069 \end{matrix} \quad \text{Eq. 6}$$

$$G = 0.114\pi - 0.1037 \quad \begin{matrix} n & r & s \\ 10 & 0.942 & 0.045 \end{matrix} \quad \text{Eq. 7}$$

groups were the most poorly predicted substituents by Eq. 6 suggests that the steric effect of the 5-substituent plays a role in toxicity. Eq. 7 rationalized 88.7% of the variance in the data. The G values calculated from Eq. 7 are given in Table IV, in comparison with their original values and hydrophobic parameters, π . Eq. 7 indicates that the more hydrophobic the substituent at the 5-position, the stronger the acute toxicity.

2) Anti-inflammatory Effect of Trioxoperhydropyrimidine Derivatives

The anti-inflammatory effect of the trioxoperhydropyrimidine derivatives, shown in Table V, on rat paw edema induced by dextran, ovalbumin and carrageenin was measured by Senda, Izumi and Fujimura.^{3a)} In their report, the inhibitory effect of these compounds was divided into five grades, $\equiv$, $\equiv$, $\equiv$, $\equiv$, $\equiv$, corresponding to 100—66%, 65—51%, 50—26%, 25—16%, and 15—0% inhibition, respectively. Intermediate values for the per cent of inhibition in the individual grades were adopted for the analysis. Thus, Y values of 83, 58, 38, 21 and 8 were assigned to the activities expressed as $\equiv$, $\equiv$, $\equiv$, $\equiv$ and $\equiv$, respectively.

6) C. Hansch and T. Fujita, *J. Am. Chem. Soc.*, **86**, 1616 (1964).

7) T. Fujita, J. Iwasa, and C. Hansch, *J. Am. Chem.*, **86**, 5175 (1964).

TABLE IV. Group Contribution Values and the Hydrophobicity of Substituent R_5

R_5 Substituent	$\pi^{a)}$	G value	
		Original	Calcd. from Eq. 7
CH_3	0.0	-0.106	-0.104
C_2H_5	0.5	-0.073	-0.047
C_3H_7	1.0	-0.015	0.011
iso- C_3H_7	0.8	0.049	-0.012
$CH_2CH=CH_2$	0.7	0.020	-0.024
C_4H_9	1.5	0.025	0.068
iso- C_4H_9	1.3	0.046	0.045
C_5H_{11}	2.0	0.055	0.125
C_6H_{13}	2.5	0.232	0.182
C_8H_{17}	3.5	0.306	0.296

a) π values were recalculated from those in Ref. 7 by shifting the standard to a CH_3 -group ($\pi CH_3=0$).

TABLE V. Observed and Calculated Anti-inflammatory Effects of Trioxoperhydropyrimidine Derivatives

	R ₁	R ₃	R ₅	Ovalbumin		Dextran		Carrageenin						
				Obsd.	Calcd.	Obsd.	Calcd.	Obsd.	Calcd.					
1	Cyc-C ₆ H ₁₁	H	CH ₃	≡	≡	1.761 ^{a)}	≡	≡	1.621 ^{b)}	—	—	— ^{c)}		
2			C ₂ H ₅	≡	≡	1.724	≡	≡	1.510	—	—	—		
3			C ₃ H ₇	≡	≡	1.673	≡	≡	1.562	—	—	—		
4			iso-C ₃ H ₇	≡	≡	1.666	+	≡	1.517	—	—	—		
5			CH ₂ CH=CH ₂	≡	≡	1.807	≡	≡	1.724	≡	≡	1.709		
6			C ₄ H ₉	≡	≡	1.738	≡	≡	1.651	≡	≡	1.681		
7			iso-C ₄ H ₉	≡	≡	1.717	≡	≡	1.663	—	—	—		
8			sec-C ₄ H ₉	≡	≡	1.625	±	+	1.233	—	—	—		
9			C ₅ H ₁₁	≡	≡	1.713	+	≡	1.529	—	—	—		
10			sec-C ₅ H ₁₁	≡	≡	1.588	≡	≡	1.571	—	—	—		
11			C ₆ H ₁₃	≡	≡	1.580	±	±	0.903	—	—	—		
12			C ₈ H ₁₇	≡	≡	1.580	≡	≡	1.580	—	—	—		
13			Cyc-C ₆ H ₁₁	≡	≡	1.813	≡	≡	1.613	—	—	—		
14			C ₆ H ₅	+	≡	1.541	≡	≡	1.499	—	—	—		
15	C ₆ H ₅	H	CH ₃	≡	≡	1.497	+	≡	1.505	±	±	0.959		
16			C ₂ H ₅	+	≡	1.460	+	+	1.395	±	±	0.936		
17			C ₃ H ₇	+	+	1.409	≡	≡	1.446	±	±	0.903		
17'			iso-C ₃ H ₇	—	—	—	—	—	—	±	±	0.903		
18			CH ₂ CH=CH ₂	≡	≡	1.543	≡	≡	1.608	±	±	0.997		
19			C ₄ H ₉	+	≡	1.474	≡	≡	1.535	±	±	0.969		
19'			C ₅ H ₁₁	—	—	—	—	—	—	±	±	0.871		
20			Cyc-C ₆ H ₁₁	≡	≡	1.549	≡	≡	1.498	±	±	1.043		
21			C ₆ H ₅	+	+	1.277	+	+	1.383	±	±	0.936		
22			Cyc-C ₆ H ₁₁	Cyc-C ₆ H ₁₁	CH ₃	≡	≡	1.670	≡	≡	1.638	+	±	1.156
23					C ₂ H ₅	≡	≡	1.633	+	≡	1.528	—	—	—
24	C ₃ H ₇	≡			≡	1.582	≡	≡	1.579	—	—	—		
25	CH ₂ CH=CH ₂	≡			≡	1.716	≡	≡	1.741	—	—	—		
26	C ₄ H ₉	≡			≡	1.647	≡	≡	1.668	±	±	1.166		
27	iso-C ₄ H ₉	≡			≡	1.626	≡	≡	1.680	—	—	—		
28	sec-C ₄ H ₉	≡			≡	1.534	≡	≡	1.250	—	—	—		
29	C ₅ H ₁₁	≡			≡	1.622	≡	≡	1.546	—	—	—		
30	sec-C ₅ H ₁₁	+			≡	1.497	≡	≡	1.589	±	±	0.903		
31	Cyc-C ₆ H ₁₁	≡			≡	1.722	≡	≡	1.631	—	—	—		
32	C ₆ H ₅	≡			≡	1.450	≡	≡	1.516	—	—	—		

	R ₁	R ₃	R ₅	Ovalbumin			Dextran			Carrageenin		
				Obsd.	Calcd.		Obsd.	Calcd.		Obsd.	Calcd.	
33	Cyc-C ₆ H ₁₁	C ₆ H ₅	CH ₃	+++	+++	1.764	+++	++	1.643	—	—	—
34			C ₂ H ₅	+++	+++	1.727	++	++	1.533	—	—	—
35			C ₃ H ₇	+++	++	1.676	++	++	1.584	—	—	—
36			iso-C ₃ H ₇	++	++	1.669	++	++	1.540	—	—	—
37			CH ₂ CH=CH ₂	+++	+++	1.810	+++	+++	1.746	++	+++	1.772
38			C ₄ H ₉	++	+++	1.741	++	++	1.673	++	+++	1.744
39			C ₅ H ₁₁	++	+++	1.716	++	++	1.551	—	—	—
40			Cyc-C ₆ H ₁₁	+++	+++	1.815	++	++	1.636	—	—	—
41	C ₆ H ₅	C ₆ H ₅	CH ₃	+	++	1.500	+	++	1.528	±	±	1.023
42			C ₂ H ₅	++	++	1.463	++	++	1.418	—	—	—
43			C ₃ H ₇	+	+	1.412	+	++	1.469	—	—	—
44			iso-C ₃ H ₇	++	+	1.405	++	++	1.425	—	—	—
45			CH ₂ CH=CH ₂	++	++	1.546	++	++	1.631	+	±	1.061
46			C ₄ H ₉	+	++	1.477	+	++	1.558	±	±	1.032
47			C ₅ H ₁₁	++	++	1.452	++	++	1.436	±	±	0.935
48			Cyc-C ₆ H ₁₁	++	++	1.551	++	++	1.521	+	±	1.107
49			C ₆ H ₅	+	+	1.279	+	+	1.406	—	—	—
50	Cyc-C ₆ H ₉	H	CH ₃	—	—	—	—	—	—	+++	+++	1.754
51			C ₂ H ₅	—	—	—	—	—	—	+++	+++	1.731
52			CH ₂ CH=CH ₂	—	—	—	—	—	—	+++	+++	1.792
53			C ₄ H ₉	—	—	—	—	—	—	+++	+++	1.764
54			Cyc-C ₆ H ₁₁	—	—	—	—	—	—	+++	+++	1.838
55			C ₆ H ₅	—	—	—	—	—	—	+++	+++	1.731

a) Calculated from *G* values obtained from Eq. 8, shown in Table III.

b) Calculated from *G* values obtained from Eq. 9, shown in Table III.

c) Calculated from *G* values obtained from Eq. 10, shown in Table III.

As with acute toxicity, the most significant correlations were obtained for regression analysis based on model A. Eqs. 8, 9 and 10 were derived by using this model for the anti-inflammatory effect on rat paw edema induced by dextran, ovalbumin and carrageenin, respectively. In each of these three equations,

For ovalbumin induced edema:

$$\log Y = \sum G_i X_i + c \quad n=49 \quad r=0.807 \quad s=0.122 \quad F=3.73 \quad \begin{matrix} (\phi_1) \\ (\phi_2) \\ (16) \\ (32) \end{matrix} \quad \text{Eq. 8}$$

For dextran induced edema:

$$\log Y = \sum G_i X_i + c \quad n=49 \quad r=0.746 \quad s=0.156 \quad F=2.51 \quad \begin{matrix} (16) \\ (32) \end{matrix} \quad \text{Eq. 9}$$

For carrageenin induced edema:

$$\log Y = \sum G_i X_i + c \quad n=27 \quad r=0.958 \quad s=0.161 \quad F=11.03 \quad \begin{matrix} (13) \\ (13) \end{matrix} \quad \text{Eq. 10}$$

the *F* ratio between the variances of the calculated and observed activities was significant at the 97.5% level. The activity contribution values, *G*, for each of the anti-inflammatory effects obtained using Eqs. 8, 9 and 10 are given in Table III. The calculated total activities of each compound from Eqs. 8, 9 and 10 are shown in Table V.

Discussion

The *G* values for acute toxicity, shown in Table III, clearly indicate that compounds which have a phenyl group at the 1-position, R₁; and a cyclohexyl group at the 3-position, R₃;

may be expected to have the least toxicity. However, when these compounds are administered, they will dissociate into ions and the cyclohexyl group, which is the more lipophilic of the two substituents, will bind to the ρ_1 area on the receptor site resulting in the same toxicity as the corresponding compounds with a cyclohexyl group at the 1-position and a phenyl group at the 3-position have. Consequently they must be fairly toxic contrary to our initial expectation.

For the compounds used in the present work, there are five possible pairs of substituents at the 1- and 3-positions. The weakest toxicity is expected for derivatives having a phenyl group and a hydrogen atom at the 1- and 3-positions, respectively, but their anti-inflammatory effect will be very weak as well. In contrast, the strongest anti-inflammatory effect is expected for derivatives having cyclohexyl and phenyl groups at the 1- and 3-positions, respectively; but they will be very toxic. The best pair of substituents for the 1- and 3-positions would be a cyclohexyl group and hydrogen atom since a moderately weak toxicity and moderately strong anti-inflammatory effect are predicted for this pair.

As for substituent R_5 , it is obvious from Eqs. 6 and 7 that methyl and ethyl groups which are less lipophilic than other groups contribute to a weakening of the toxicity, whereas a large lipophilic substituent, *i.e.* hexyl and octyl groups, leads to fairly toxic compounds. Anti-inflammatory activities seem to have no direct relation to the lipophilicity of substituent R_5 . Allyl, butyl, cyclohexyl and methyl groups at the 5-position enhance the anti-inflammatory effect. Thus, as the most suitable anti-inflammatory agents in terms of their activity and toxicity, 1-cyclohexyl-5-methyl, -5-allyl, and -5-butyl derivatives would be selected from this series of compounds. In fact, the clinically used, anti-inflammatory agent, Bucolome^R, belongs to this group.

Acknowledgement The authors are grateful to Dr. S. Senda, Gifu College of Pharmacy, and Dr. H. Fujimura, Gifu University, for their generosity in permitting the use of their data, and to Dr. S. Tatsuoka, the director of this division, for his encouragement throughout this work.